CLERICO, Marinella

CLERICO, Marinella  

SCIENZE CLINICHE E BIOLOGICHE  

Mostra records
Risultati 1 - 20 di 256 (tempo di esecuzione: 0.041 secondi).
Titolo Data di pubblicazione Autore(i) File
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b 2006 A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b 2006 A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A COCHRANE meta-analysis on the efficacy of recombinant interferon beta in preventing conversion of clinically isolated syndromes 2006 M. CLERICO; F. FAGGIANO; J. PALACE; M. TINTOR; G. RICE; L. DURELLI
A COCHRANE review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to Multiple Sclerosis 2006 M. CLERICO; M. TINTORE' SUBIRANA; J. PALACE; G. RICE; F. FAGGIANO; L. DURELLI
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. 2004 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 2011 Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis 2006 Durelli, Luca; Barbero, Pierangelo; Clerico, Marinella
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab 2017 Clerico, Marinella; De Mercanti, Stefania; Artusi, Carlo Alberto; Durelli, Luca; Naismith, Robert T
The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View 2019 Maglione, Alessandro; Rolla, Simona; Mercanti, Stefania Federica De; Cutrupi, Santina; Clerico, Marinella
Adherence to interferon-beta treatment and results of therapy switching 2007 Clerico, Marinella; Barbero, Pierangelo; Contessa, Giulia; Ferrero, Cinzia; Durelli, Luca
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 2016 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 2016 Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 2016 De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 2012 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study 2018 Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study 2014 A. Chiò;A. Calvo;G. Bovio;A. Canosa;D. Bertuzzo;F. Galmozzi;P. Cugnasco;M. Clerico;S. De Mercanti;E. Bersano;S. Cammarosano;A. Ilardi;U. Manera;C. Moglia;R. Sideri;K. Marinou;E. Bottacchi;F. Pisano;R. Cantello;L. Mazzini;G. Mora; Piemonte;V. d. Register
Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation 2005 A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; M. CLERICO; B. FERRERO; A. ROVERA; L. GIORDANO; G. CONTESSA; E. FESTA; L. DURELLI; ON BEHALF OF THE OPTIMS TRIAL STUDY GROUP
Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD). 2003 M. CLERICO; E. ROTA; A. RICCI; E. VERDUN; P. BARBERO; A. PIPIERI; A. CUCCI; L. GIORDANO; L. DURELLI
Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study 2015 Calvo, A; Moglia, C; Canosa, A; Bertuzzo, D; Galmozzi, F; Cugnasco, P; Clerico, M; De Mercanti, S; Bersano, E; Cammarosano, S; Ilardi, A; Manera, U; Sideri, R; Marinou, K; Bottacchi, E; Pisano, F; Cantello, R; Mazzini, L; Mora, G; Chiò, A
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study 2017 Laroni, Alice; Signori, Alessio; Maniscalco, Giorgia T.; Lanzillo, Roberta; Russo, Cinzia Valeria; Binello, Eleonora; Lo Fermo, Salvatore; Repice, Annamaria; Annovazzi, Pietro; Bonavita, Simona; Clerico, Marinella; Baroncini, Damiano; Prosperini, Luca; La Gioia, Sara; Rossi, Silvia; Cocco, Eleonora; Frau, Jessica; Torri Clerici, Valentina; Signoriello, Elisabetta; Sartori, Arianna; Zarbo, Ignazio Roberto; Rasia, Sarah; Cordioli, Cinzia; Cerqua, Raffaella; Di Sapio, Alessia; Lavorgna, Luigi; Pontecorvo, Simona; Barrilã , Caterina; Saccã , Francesco; Frigeni, Barbara; Esposito, Sabrina; Ippolito, Domenico; Gallo, Fabio; Sormani, Maria Pia